

### Remarks

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Claims 1, 45, and 46 have been amended to more specifically define the steroid hormone derivative as "a C11, C17, or C21 hydroxy derivative." Descriptive support for this limitation appears at page 13, lines 23-24, of the present application. Claims 1-11, 13-33, 35, 37, 39-41, 43, and 45-60 remain pending. No excess claim fees are due with this response.

The applicant would like to thank Examiner Ha for the courtesy extended to the undersigned representative during the telephone conferences held on January 14 and 17, 2008, in which the sole basis of rejection and the above amendments were discussed. Agreement was reached during the January 17, 2008, telephone conference that the above amendments overcome the basis of rejection.

Because the present application provides sufficient written descriptive support for the above-noted classes of steroid hormone derivatives, applicants respectfully request withdrawal of the rejection of claims 1-11, 15-26, 29-33, 35, 37, 39-41, 43 and 45-60 under 35 U.S.C. § 112 (1<sup>st</sup> para.) as failing to comply with the written description requirement.

The objection to claims 13, 14, 27, and 28 is rendered moot by the above amendments, which overcome the sole remaining basis of rejection. Therefore, the objection should be withdrawn.

In view of all the foregoing, it is submitted that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: March 12, 2008

/Edwin V. Merkel/  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
1100 Clinton Square  
Rochester, New York 14604  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600